Dr. Mathew Samuel Kalarickal, a pioneer of interventional cardiology, has passed away on April 18, 2025, in Chennai, at the age of 77, marking an end to an era in coronary angioplasty and stenting technology. Popularly known as the 'Father of Angioplasty in India,' Dr. Kalarickal transformed heart care, changing the lives of thousands of patients and redefining the face of contemporary interventional cardiology.

Born on January 6, 1948, in Kerala, Dr. Kalarickal's journey to becoming one of the world's most renowned cardiologists was set early in life. After completing his medical studies at Kottayam Medical College, he went on to pursue specialization in cardiology from Chennai but his stint in the United States of America, under the guidance of Dr. Andreas Gruentzig—the man universally accepted as the 'Father of Coronary Angioplasty'—would establish the foundation for his groundbreaking career.

Dr. Kalarickal's return to India in 1985 proved to be turning point. Coronary angioplasty was a new, unexplored area in India at that time, and one that fell behind progress in the U.S. and Europe. Sensing this lacuna, Dr. Kalarickal chose to introduce this revolutionary procedure to India, with a vision of making lifesaving heart procedures reach more people.

First Angioplasty in India

In 1986, Dr. Kalarickal performed the very first angioplasty in India, a process which would subsequently alter the direction of heart treatment in the country. Angioplasty at that time was not a widely known procedure in India, and coronary artery disease was on the rise. During the first year, he had only treated 18 patients. But by 1987, that figure had risen to 150, an unmistakable indicator of both the increasing demand for this life-saving operation and the confidence that patients had in Dr. Kalarickal's skills.

His success in India did not remain confined to its borders, Dr. Kalarickal played a key role in setting up angioplasty centers in various nations in the Asia-Pacific region, such as Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Indonesia, Thailand, and Malaysia. His relentless efforts to educate and train physicians in these nations helped ensure that this new technique spread like wildfire, eventually saving countless lives and making heart procedures more available worldwide.

Role of Dr. Kalarickal in Expanding Angioplasty Globally

Dr. Kalarickal's role was not just to bring angioplasty to India and the rest of the region. As an innovator, he was a pioneer in bringing new innovations to the world of angioplasty and stenting. One of his greatest feats was becoming the first Indian cardiologist to introduce and practice the application of drug-eluting bio-absorbable stents, which improved the efficacy of angioplasty by a large margin and minimized the threat of re-blockage in coronary arteries.

Having done more than 10,000 angioplasties, Dr. Kalarickal's expertise and commitment to improving heart health were second to none. He also contributed significantly to academia, establishing the National Angioplasty Registry of India, through which data on angioplasty operations could be gathered and analyzed to streamline and enhance practice nationwide. His contributions had an effect on the medical fraternity and made him a mentor to numerous budding cardiologists in India and overseas.

Dr. Kalarickal's success was not limited to the operating room. His leadership positions in major medical societies demonstrate his reputation as a world leader in interventional cardiology. He was president of the Asian-Pacific Society of Interventional Cardiology from 1995 to 1997 and then went on to chair the Asian-Pacific Society of Cardiology section of Interventional Cardiology between 1995 and 1999. His presidency in these societies promoted the use of angioplasty and stenting procedures around the world and consolidated the group of cardiologists in Asia.

His work was duly appreciated in many awards and honors. Dr. Kalarickal received the esteemed Padma Shri award in 2000, one of the highest civilian awards in India, for his outstanding work in cardiology. He was also awarded the Dr. B.C. Roy Award in 1996 for his notable contributions to medicine, the Doctor of Science Award by Dr. M.G.R. University in 2003, and a Lifetime Achievement Award in 2008.

While Dr. Kalarickal was well-known for his medical knowledge, he was as much admired for being a mentor. Dr. Sai Satish, who is a senior interventional cardiologist in Chennai, was trained by Dr. Kalarickal and collaborated with him for more than two decades. Talking about his experiences during his mentor's time, Dr. Satish stated, "There will never be another Dr. Mathew Samuel Kalarickal in my life.". He taught me in ways that few people ever managed, and I will miss him every time I enter a cath lab." This is a sentiment shared by many other cardiologists who were fortunate enough to learn from him. His dedication to educating and empowering the future generation of heart doctors has left an invaluable legacy on the specialty of cardiology.

Dr. Kalarickal's contributions have saved thousands of lives, and his legacy will never be lost in the profession of interventional cardiology. His vision, commitment, and pioneering attitude have revolutionized heart disease treatment in India and across the globe. With the advent of angioplasty, he revolutionized the procedure that used to be an extremely invasive and dangerous one and turned it into a routine, life-saving one.

How Angioplasty Saves Your Heart?

Angioplasty is a minimally invasive procedure to open up narrowed or blocked coronary arteries due to a buildup of fatty plaques. Plaque buildup in the arteries over time can limit blood supply to the heart, resulting in angina (chest pain) or even heart attacks. Angioplasty is done to relieve these blockages, restore normal blood flow, and prevent heart-related complications. But in what way precisely does angioplasty save the heart?

While undergoing angioplasty, a catheter is inserted into the clogged artery with a balloon at the end. The catheter is advanced through the bloodstream with great caution until it enters the area where the blockage is. Having reached its destination, the balloon is inflated, pushing the plaque against the artery walls, effectively opening up the artery and reinstating blood circulation to the heart. In most instances, a tiny mesh tube known as a stent is also inserted to keep the artery open and prevent it from closing again.

Angioplasty can be carried out in patients with different types of coronary artery disease, such as patients who have experienced heart attacks, those with chronic angina, and those at high risk for cardiac events due to plaque deposition. Angioplasty is commonly carried out on patients who are not ideal candidates for standard open-heart surgery.

Instant Relief and Long-term Advantages

Perhaps the greatest benefit of angioplasty is the relief that it brings promptly to the patient. Post-procedure, patients can notice dramatically decreased symptoms of chest pain, shortness of breath, and tiredness, all typical with clogged arteries. The normalization of blood flow tends to keep the heart from working as hard and lowers the risk of heart attacks.

In the long run, angioplasty ensures that the heart is not subjected to further harm by providing it with a sufficient supply of oxygenated blood. This is particularly vital in individuals suffering from coronary artery disease because continuous blood flow is crucial to maintaining heart muscle health. Angioplasty can greatly eliminate the risk of heart failure, heart attack, or stroke by opening up clogged arteries. Also, the procedure has been demonstrated to enhance quality of life in general, since patients are frequently able to resume normal activities following the procedure without the restrictions created by chest pain and other symptoms.

Patients taking a widely used blood pressure drug are being advised to verify their medication after a batch was recalled due to incorrect dosage information printed on the packaging. According to the Medicines and Healthcare Products Regulatory Agency (MHRA), some packs of lercanidipine, manufactured by Recordati Pharmaceuticals, have been wrongly labelled as containing 10mg tablets, when in fact they contain 20mg tablets.

Over 7000 Packs Are Subject To Recall

More than 7,700 packs already distributed are now subject to the recall, the MHRA has confirmed. Patients who may have the mislabelled medication are being urged to contact their GP, pharmacist, or call NHS 111 for advice. The NHS warns that consuming an excessive dose of lercanidipine can lead to symptoms such as dizziness and drowsiness. The MHRA issued the alert on Thursday after being informed by the Italian pharmaceutical company Recordati that the error was confined to a single batch of lercanidipine, which was initially distributed on April 10. The recalled packs carry the batch number MD4L07 and are marked with an expiry date of January 2028.

Although the front of the affected packs displays the incorrect strength, the correct 20mg dose is printed on the blister strips inside and on the side of some of the boxes. The MHRA advises patients who have been prescribed the 20mg dose to check the blister packaging to ensure they have received the correct medication. However, those prescribed 10mg tablets should seek immediate medical attention if they have this batch.

As a temporary measure, the MHRA suggests that patients who cannot reach a healthcare provider may take half of a 20mg tablet until they receive professional guidance. Dr Alison Cave, the MHRA’s chief safety officer, stated: "Healthcare professionals such as pharmacists are also being asked to stop supplying medicine from the affected batch and to return it to the supplier." She encouraged anyone experiencing suspected side effects to report them through the MHRA’s Yellow Card scheme.

In a statement to the BBC, a spokesperson for Recordati said the company is "working proactively" with the MHRA and will contact all customers who might have received the affected batch. “We are investigating the root cause and continue to work with our partners to isolate the issue and minimise disruption to our patients. Patient safety remains our top priority,” the spokesperson added.

What Do We Know About Lercanidipine?

Lercanidipine is used in the treatment of Angina (heart-related chest pain), Hypertension (high blood pressure), Arrhythmia, hypertensive emergency, subarachnoid haemorrhage and anal fissure. According to the NHS, it is one of the four types of blood pressure medicines sold across the UK. These pills are a calcium channel blocker. That means it regulates blood pressure by relaxing blood vessels and reducing pressure on them, thereby making it easier for the heart to pump more blood throughout the body. In this way, it normalises the blood pressure in patients with high blood pressure.

ALSO READ: RFK Jr.'s Autism Controversial Comments Face Backlash From Parents And Medical Experts

Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, is facing strong backlash after making sweeping comments during a recent press conference regarding autism and its supposed causes. As the CDC released a report revealing a rise in autism diagnoses among U.S. children now affecting 1 in 31 8-year-olds Kennedy doubled down on discredited theories linking autism to environmental exposures and vaccines, while portraying the disorder in stark, stigmatizing terms.

His remarks including claims that children with autism “will never hold a job,” “never pay taxes,” or “never use a toilet unassisted”, were swiftly condemned by parents, medical experts, and advocacy groups alike for reinforcing outdated stereotypes and misrepresenting the broad and diverse autism spectrum.

Autism spectrum disorder (ASD) is not a single condition with uniform symptoms or outcomes. Rather, it is a neurological and developmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. The key word is "spectrum" and it exists for a reason.

Some individuals with autism may be nonverbal and need lifelong support, while others live independently, excel in careers, write books, or even hold public office. “Autism is not a disease,” said actress and autism advocate Holly Robinson Peete in a video statement, responding to Kennedy. “It is a developmental difference and it is important to get that right.”

Her son, RJ, diagnosed 25 years ago, has “shattered a lot of 'never' off that list,” she said, referring to Kennedy’s grim portrayal. Countless parents echoed this sentiment on social media, stating that Kennedy’s generalizations erase the lived realities, milestones, and accomplishments of their children.

CDC Data Shows a Rise in Diagnoses

The CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network reported that 1 in 31 8-year-olds in the U.S. were diagnosed with autism in 2022, compared to 1 in 54 in 2016. But experts stress that this increase is not necessarily cause for alarm. It is, in fact, a sign of progress.

The rise in autism rates is driven largely by improved awareness, broader diagnostic criteria, and increased access to evaluations and services. We are identifying children earlier and more accurately that’s a good thing.

Kennedy, however, rejected this explanation as “indefensible” and announced plans for a directive to the National Institutes of Health to investigate “environmental exposures” as the root cause — reigniting long-debunked concerns about vaccines and toxins.

Despite overwhelming scientific consensus debunking any link between vaccines and autism, Kennedy has long been associated with promoting vaccine hesitancy. His latest comments, veiled in language about “environmental exposures,” once again hint at this discredited narrative.

Leading medical organizations, including the American Academy of Pediatrics and the World Health Organization, have repeatedly emphasized that vaccines are safe, effective, and have no causal relationship with autism. Resurrecting these claims only spreads fear and confusion. It undermines public health and harms autistic people by framing their existence as a preventable tragedy.

Parents Demand a Shift in the Narrative

Perhaps the strongest rebuke came from parents of autistic children themselves. Samantha Taylor, whose 20-year-old son is on the spectrum, told Good Morning America, “Autism doesn’t destroy families misinformation does.” In a viral Facebook post, she added, “What truly causes damage is the relentless portrayal of autism as something catastrophic, rather than a different way of experiencing the world.”

Kennedy’s comments, they say, not only ignore the complexity of the condition but strip children of their dignity and potential.

“Statements like ‘they’ll never write a poem’ deny the creative genius that so many autistic individuals demonstrate,” said Peete. “It’s dangerous, it’s harmful, and it’s simply false.”

Experts Call for More Informed Leadership

While Kennedy has promised answers by September through federally backed studies, medical experts warn that his rhetoric may set back years of advocacy and research by framing autism as an “epidemic” akin to an infectious disease.

Autism is not something to be eradicated, it’s something to be understood, supported, and embraced. Families deserve resources, not fearmongering.

In the last two decades, the medical community has shifted toward neurodiversity — a perspective that recognizes neurological differences like autism as natural variations of the human genome. This philosophy emphasizes inclusivity, respect, and strength-based approaches rather than medicalizing difference.

At a time when public trust in institutions is fragile, the words of public officials matter deeply. Kennedy’s comments have triggered a reckoning not only about how autism is portrayed in the media and politics but also about how society chooses to value — or devalue — people who are different.

Advocates stress the need for policies rooted in science, not stigma, and for leadership that uplifts rather than marginalizes.

As the national conversation around autism continues, one thing is clear: the autism community — parents, children, adults on the spectrum, clinicians, and allies — is not going to stay silent in the face of outdated narratives.

On World Liver Day, which is observed on April 19, to spread awareness about liver health and the life-saving power of organ donation, let us look at one such real-life story. This is where doctor's prompt's action and one's selfless donation saved one human's life.

When the 30-year-old Delhi-based man walked into the hospital, he had yellow eyes and dangerously high liver enzymes. He was admitted in Max Super Speciality Hospital, Patparganj. That moment, he rarely knew that his life was, in fact, hanging by a thread. The man was diagnosed with acute liver failure, which was caused by viral hepatitis. His body was slowly shutting down. The frequency of his body shutting down had increased. The doctors also quickly informed the family. This was the one last hope of survival - a liver transplant.

The First Option Failed

His sister was family's first ray of hope. She was also willing and had a compatible liver whose part of it could be donated. However, pre-surgery tests revealed that her liver size was too small to ensure a safe transplant. The family then proposed the patient's brother-in-law - a second-degree relative, as the next donor. His liver was a better match, but since he was not an immediate blood relative, there had to be special regulatory approvals which were required.

However, the worsening condition of the patients allowed no such time.

The hospital too scrambled to get clearance for the brother-in-law. All this while, the patient suffered a cardiac arrest. The situation turned dire within minutes. Doctors performed CPR to revive him. He was immediately put on ventilator support. The decision had to be taken soon.

A Miraculous Surgery

With no time in hand, the doctors decided to go ahead with the sister as the donor, though there were risks there too.

A team of highly skilled hepatobiliary surgeons, anesthesiologists, and critical care specialists took over. In a high-risk, nine-hour surgery, they removed the patient’s failing liver and replaced it with part of his sister’s.

“This was one of the most challenging cases we’ve handled,” said Dr. Ajitabh Srivastava, Director – HPB Surgery & Liver Transplant. “When the patient collapsed, our team acted within seconds. Every decision, every move mattered. His survival was truly a team triumph.”

The patient is now recovering well.

What Is A Liver Transplant?

As per the National Institute of Diabetes and Digestive and Kidney Diseases, a liver transplant is a surgical procedure to replace a diseased liver with a healthy one from a donor. It’s often the last resort when liver failure occurs—whether due to chronic illness or sudden injury.

When Is It Needed?

People may need a liver transplant for:

• Alcoholic liver disease
• Fatty liver disease (NASH)
• Cirrhosis due to chronic hepatitis C
• Liver cancer with cirrhosis
• Acute liver failure (often due to drug overdose, hepatitis, or toxins)

In children, biliary atresia is the most common reason.

Types of Liver Transplants

Deceased Donor Transplant:

The most common type, where a full or partial liver is taken from someone who has recently died.

Living Donor Transplant:

A healthy person donates a portion of their liver—typically a close relative. Both the donor’s and recipient’s liver regenerate to normal size in a few weeks.

What Must Be Kept In The Mind?

• Matching and Compatibility: Blood type, liver size, and health are crucial.
• Approval Process: Especially important for non-blood relatives.
• Recovery and Monitoring: Post-op care involves lifelong medication, lifestyle changes, and regular check-ups.